Tumour radiosensitization by clofibrate and its analogs: possible mechanisms.
Hirst
D G
DG
CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middx., England.
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D002994:Clofibrate / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017341:Etanidazole; D005260:Female; D000860:Hypoxia / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism; D011838:Radiation-Sensitizing Agents; D012039:Regional Blood Flow / Q000187:drug effects
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C028764:etofylline clofibrate; D017341:Etanidazole; D002994:Clofibrate; D010100:Oxygen; D001629:Bezafibrate